Multitude Therapeutics focuses on developing innovative therapeutic solutions through its proprietary technologies aimed at addressing unmet medical needs. The company specializes in the design and optimization of RNA-based therapeutics, leveraging its expertise in RNA delivery systems to enhance the efficacy and safety of treatments. Their platform enables the targeted delivery of RNA molecules, which can modulate gene expression and provide a novel approach to treating various diseases, including genetic disorders and cancers.

In addition to RNA therapeutics, Multitude Therapeutics is advancing its capabilities in the field of gene editing. The company employs cutting-edge techniques to precisely edit genes, allowing for the correction of genetic mutations at the source. This technology holds significant promise for developing curative therapies for a range of genetic conditions. By integrating these advanced methodologies, Multitude Therapeutics aims to create a robust pipeline of products that can transform patient care and improve health outcomes.

United States

Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy.  MTX focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts and immuno-oncology antibodies for solid and hematological tumors. MTX's therapeutic programs are based on novel cancer and immune cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.

Multitude Therapeutics

Company Details